Why this ASX medical technology share is up 11% today

The Next Science Ltd (ASX:NXS) share price is racing higher today, following the release of an update regarding the coronavirus and US sales.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price is racing higher today, up by 11.38% at the time of writing, following the release of an update regarding the coronavirus and the company's sales activities in the US.

Impact on sales in the US market

The medical technology company revealed in its announcement today that it is seeing an impact on its activities due to the coronavirus outbreak in the US, with a reduction in new client growth. This is being driven by a reduction in the number of visits by its distribution agents to hospitals, the postponement of some medical congresses and also a reduction by hospitals in the number of elective surgery procedures.

Next Science added that it is not yet in a position to forecast sales demand for the second quarter of 2020, as the duration of the US' national status of emergency is currently unknown.

Potential benefit from coronavirus outbreak

Next Science stated that it currently has a number of products either currently launched, or expected to be launched, later this year that are effective in the removal of viruses similar to the coronavirus.

The company, therefore, expects to reap some benefit from the global increased focus and awareness on infection prevention in general. Next Science believes this will extend over the longer-term, well beyond the current duration of the coronavirus crisis.

Next Science noted that it currently has three products that are effective in the removal or prevention of coronavirus-like viruses and bacteria: one used in the surgical field, one in relation to infected wounds and one used for surgical procedures.

On March 3, Next Science shares soared higher after the company released an update on its Bactisure surgical lavage and revealed that had received its CE mark approval for the product.

Next Science has two products that it is currently seeking regulatory approval for in the US that further address infection: a surface disinfectant and a surgical rinse. The company is anticipating commercial launch of these products in the second half of FY 2020.

Five new products still on track to be launched in 2020

In total, Next Science is anticipating the launch of five new products during 2020 and doesn't expect the current coronavirus outbreak to impact this timeline, as work on product and regulatory testing continues.

The company has put in place an infection management policy in its Jacksonville facilities to ensure that safety and business continuity is maintained throughout the period of the current crisis.

Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three women dance and splash about in the shallow water of a beautiful beach on a sunny day.
Energy Shares

ASX 200 energy sector leads the market ahead of OPEC+ meeting

OPEC+ will meet today to decide whether to maintain its pause on oil production increases.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Broker Notes

Buy, hold, sell: Amcor, ANZ, and Macquarie shares

Does a leading broker think investors should be buying these blue chips? Let's find out.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Opinions

Where I'd invest $10,000 in 2026 in ASX shares aiming to beat the market

These businesses look like very appealing buys today.

Read more »

a woman with lots of shopping bags looks upwards towards the sky as if she is pondering something.
Opinions

The pros and cons of buying Zip shares in 2026

There are positive and negative aspects about Zip shares right now…

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Buy, hold, sell: CBA, REA Group, and Xero shares

Morgans has given its verdict on these popular stocks. Let's see if it is bullish on them.

Read more »

A man in a suit looks serious while discussing business dealings with a couple as they sit around a computer at a desk in a bank home lending scenario.
Share Market News

Here's what Westpac says the RBA will do with interest rates in 2026

Stick or twist? Let's see what the RBA could do with rates this year.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Best Shares

Fastest rising ASX 200 share of each market sector in 2025

These shares outperformed their sector peers last year.

Read more »